$475.2 M

AKBA Mkt cap, 20-Sep-2018
Akebia Therapeutics Net income (Q2, 2018)-57.5 M
Akebia Therapeutics EBIT (Q2, 2018)-60.2 M
Akebia Therapeutics Cash, 30-Jun-2018163.5 M

Akebia Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

R&D expense

25.4 m43 m115.8 m230.9 m

General and administrative expense

12.5 m18.5 m22.2 m27 m

Operating expense total

37.9 m61.5 m138 m257.9 m

EBIT

(37.9 m)(61.5 m)(136.5 m)(79.9 m)

Interest expense

206 k510 k

Interest income

206 k510 k901 k2.8 m

Net Income

(37 m)(60.7 m)(135.7 m)(76.9 m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

R&D expense

7.5 m7.2 m15.8 m20.2 m30.9 m31.2 m60 m43.8 m61.4 m133.3 m

General and administrative expense

3.4 m3.7 m3.9 m5.8 m5.3 m4.9 m5.8 m6.9 m9 m21.6 m

Operating expense total

10.9 m10.9 m19.7 m26 m36.2 m36.2 m65.8 m50.7 m70.4 m154.9 m

EBIT

(10.9 m)(10.9 m)(19.7 m)(26 m)(36.2 m)(36.2 m)(45 m)(22.1 m)(24.5 m)(60.2 m)

Interest expense

96 k116 k139 k234 k

Interest income

96 k116 k139 k234 k270 k219 k435 k608 k1.1 m2.6 m

Net Income

(10.7 m)(10.7 m)(19.5 m)(25.8 m)(35.8 m)(36.3 m)(44.5 m)(21.5 m)(23.4 m)(57.5 m)

Akebia Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

32.8 m49.8 m187.3 m70.2 m

Accounts Receivable

48 k933 k34.2 m

Inventories

1.5 m2.6 m2.2 m

Current Assets

110.5 m141 m296.3 m358.4 m

PP&E

209.9 k540 k2.6 m3.6 m

Total Assets

111 m142.9 m300.2 m364.2 m

Accounts Payable

2 m2.3 m2 m7 m

Current Liabilities

6.9 m11.9 m114.3 m144.3 m

Total Liabilities

232.1 m244.9 m

Additional Paid-in Capital

205 m292.8 m365.3 m493.8 m

Retained Earnings

(100.7 m)(161.4 m)(297.1 m)(374.1 m)

Total Equity

104.1 m131 m68.1 m119.3 m

Financial Leverage

1.1 x1.1 x4.4 x3.1 x

Quarterly

USDQ1, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

126.3 m27.9 m76.2 m66.7 m43.4 m46.2 m65.8 m87.3 m125.4 m158.2 m163.5 m

Accounts Receivable

119.4 k74 k48 k14 k35.9 m132 k

Current Assets

133.7 m102.7 m155 m158.8 m219.5 m192.5 m165.1 m255.1 m332.4 m437 m407.4 m

PP&E

404 k398 k479 k629 k1.8 m2.7 m2.9 m2.9 m3.7 m3.7 m

Total Assets

134 m103.5 m155.7 m159.6 m221.4 m195.6 m169.1 m259.3 m336.8 m442.7 m413.8 m

Accounts Payable

2.1 m4.3 m2.4 m5.3 m2.4 m5.1 m8.5 m15.1 m10.2 m17.9 m4.8 m

Current Liabilities

6.1 m8.8 m5.9 m14.2 m13.4 m20.9 m26.1 m133.5 m181.6 m151.4 m164.4 m

Total Liabilities

6.2 m8.9 m5.9 m14.2 m53.7 m62.3 m68.4 m228.6 m279.8 m245.6 m247.9 m

Additional Paid-in Capital

201.2 m206.1 m272 m287.1 m355.1 m356.2 m360 m372.5 m420.4 m591.9 m594.7 m

Retained Earnings

(111.4 m)(122.1 m)(141.5 m)(187.2 m)(223 m)(259.3 m)(341.7 m)(363.2 m)(394.2 m)(428.3 m)

Total Equity

127.9 m94.6 m149.8 m145.4 m167.8 m133.3 m100.7 m30.6 m57 m197.1 m165.9 m

Financial Leverage

1 x1.1 x1 x1.1 x1.3 x1.5 x1.7 x8.5 x5.9 x2.2 x2.5 x

Akebia Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(37 m)(60.7 m)(135.7 m)(76.9 m)

Depreciation and Amortization

49.4 k96 k296 k617 k

Accounts Receivable

87 k(393 k)

Inventories

(773 k)(1 m)428 k

Accounts Payable

4.1 m231 k(274 k)5 m

Cash From Operating Activities

(27.5 m)(52.4 m)57.9 m(56.2 m)

Purchases of PP&E

(229 k)(414 k)(2.7 m)(1.6 m)

Cash From Investing Activities

(65.4 m)(13.7 m)12.7 m(177.3 m)

Cash From Financing Activities

104.4 m83.1 m66.9 m116.2 m

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(9.7 m)(10.7 m)(10.7 m)(19.5 m)(25.8 m)(35.8 m)(36.3 m)(44.5 m)(23.4 m)(57.5 m)

Depreciation and Amortization

8.1 k199 k413 k

Accounts Receivable

15.9 k114 k57 k74 k48 k14 k(1.6 m)34.1 m

Accounts Payable

1.9 m1.5 m3 m4.3 m2.4 m5.3 m2.4 m5.1 m8.5 m15.1 m10.9 m(2.2 m)

Cash From Operating Activities

(6 m)(20.3 m)(11.3 m)

Purchases of PP&E

(142 k)(296 k)(469 k)

Cash From Investing Activities

5.4 m12.4 m8.9 m

Cash From Financing Activities

105.8 m95.9 m96.1 m

Akebia Therapeutics Ratios

USDY, 2018

Financial Leverage

2.5 x
Report incorrect company information